Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Notebook: U.K. Early Access Scheme Starts; New HTA Body In Portugal; Doctors Oppose French Health Bill

Executive Summary

Merck’s Keytruda is made available before approval under U.K.’s new EAMS project; Portugal sets up a new technology assessment body, while Germany’s IQWIG says HTA dossiers could be a useful source of clinical trial data for other uses; in France, clinical trial lead times are lengthening and doctors protest a proposed reimbursement change.

Advertisement

Related Content

Swapping Assets Now Down To Execution For GSK And Novartis
Lifting the ‘Breakthrough’ Veil: FDA Increases Transparency To Reduce Futile Requests
Safety Profile Of Merck’s Anti-PD-1 Keytruda Shines In FDA Labeling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056731

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel